Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.

Humans Liver Cirrhosis / blood Biomarkers / blood Animals Male Mice Female Semaphorins / blood Middle Aged Fatty Liver / blood Liver / pathology Disease Models, Animal Receptors, LDL / genetics Transcriptome Mice, Knockout Adult Mice, Inbred C57BL Insulin-Like Growth Factor Binding Proteins

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
29 May 2024

Historique:

received: 23 08 2023

accepted: 20 05 2024

medline: 30 5 2024

pubmed: 30 5 2024

entrez: 29 5 2024

Statut: epublish

Résumé

Accurate non-invasive biomarkers to diagnose metabolic dysfunction-associated steatotic liver disease (MASLD)-related fibrosis are urgently needed. This study applies a translational approach to develop a blood-based biomarker panel for fibrosis detection in MASLD. A molecular gene expression signature identified from a diet-induced MASLD mouse model (LDLr-/-.Leiden) is translated into human blood-based biomarkers based on liver biopsy transcriptomic profiles and protein levels in MASLD patient serum samples. The resulting biomarker panel consists of IGFBP7, SSc5D and Sema4D. LightGBM modeling using this panel demonstrates high accuracy in predicting MASLD fibrosis stage (F0/F1: AUC = 0.82; F2: AUC = 0.89; F3/F4: AUC = 0.87), which is replicated in an independent validation cohort. The overall accuracy of the model outperforms predictions by the existing markers Fib-4, APRI and FibroScan. In conclusion, here we show a disease mechanism-related blood-based biomarker panel with three biomarkers which is able to identify MASLD patients with mild or advanced hepatic fibrosis with high accuracy.

Identifiants

DOI: 10.1038/s41467-024-48956-0 PMID: 38811591

pubmed: 38811591

doi: 10.1038/s41467-024-48956-0

pii: 10.1038/s41467-024-48956-0

doi:

Substances chimiques

Biomarkers 0

Semaphorins 0

insulin-like growth factor binding protein-related protein 1 0

Receptors, LDL 0

Insulin-Like Growth Factor Binding Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

4564

Informations de copyright

Références

Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).

pubmed: 35798021 doi: 10.1016/S2468-1253(22)00165-0

Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 78, 1966-1986 (2003).

Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

pubmed: 26707365 doi: 10.1002/hep.28431

Taylor, R. S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158, 1611–1625.e12 (2020).

pubmed: 32027911 doi: 10.1053/j.gastro.2020.01.043

Hagström, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265–1273 (2017).

pubmed: 28803953 doi: 10.1016/j.jhep.2017.07.027

Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181–194 (2014).

pubmed: 24566915 doi: 10.1038/nri3623

Diehl, A. M. & Day, C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 377, 2063–2072 (2017).

pubmed: 29166236 doi: 10.1056/NEJMra1503519

Vilar-Gomez, E. & Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J. Hepatol. 68, 305–315 (2018).

pubmed: 29154965 doi: 10.1016/j.jhep.2017.11.013

Ajmera, V. & Loomba, R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol. Metab. 50, 101167 (2021).

pubmed: 33460786 pmcid: 8324681 doi: 10.1016/j.molmet.2021.101167

Younes, R. et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J. Hepatol. 75, 786–794 (2021).

pubmed: 34090928 doi: 10.1016/j.jhep.2021.05.008

Govaere, O. et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat. Metab. 5, 572–578 (2023).

pubmed: 37037945 pmcid: 10132975 doi: 10.1038/s42255-023-00775-1

Sveinbjornsson, G. et al. Multiomics study of nonalcoholic fatty liver disease. Nat. Genet. 54, 1652–1663 (2022).

pubmed: 36280732 pmcid: 9649432 doi: 10.1038/s41588-022-01199-5

Abozaid, Y. J. et al. Plasma proteomic signature of fatty liver disease: The Rotterdam Study. Hepatology 78, 284–294 (2023).

pubmed: 36738080 doi: 10.1097/HEP.0000000000000300

European Association for the Study of the Liver. Clinical Practice Guideline Panel; EASL Governing Board representative: EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis − 2021 update. J Hepatol. 2021;75:659–689.

Rosenberg, W. M. C. et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127, 1704–1713 (2004).

pubmed: 15578508 doi: 10.1053/j.gastro.2004.08.052

Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J. Hepatol. 73, 252–262 (2020).

pubmed: 32275982 doi: 10.1016/j.jhep.2020.03.036

López, I. C. et al. Utility of the ELF test for detecting steatohepatitis in morbid obese patients with suspicion of nonalcoholic fatty liver disease. Obes. Surg. 27, 2347–2353 (2017).

pubmed: 28229316 doi: 10.1007/s11695-017-2606-9

Hinkson, A. et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol. Ther. 57, 750–762 (2023).

pubmed: 36650720 doi: 10.1111/apt.17385

Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325 (2006).

pubmed: 16729309 doi: 10.1002/hep.21178

Wu, Y. L. et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J. Gastroenterol. 27, 5753–5763 (2021). https://www.wjgnet.com/1007-9327/full/v27/i34/5753.htm .

pubmed: 34629799 pmcid: 8473595 doi: 10.3748/wjg.v27.i34.5753

Graupera, I. et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin. Gastroenterol. Hepatol. 20, 2567–2576.e6 (2022).

pubmed: 34971806 doi: 10.1016/j.cgh.2021.12.034

Castellana, M. et al. Fibrosis-4 index vs nonalcoholic fatty liver disease fibrosis score in identifying advanced fibrosis in subjects with nonalcoholic fatty liver disease: a meta-analysis. Am. J. Gastroenterol. 116, 1833–1841 (2021).

pubmed: 34160377 doi: 10.14309/ajg.0000000000001337

Alkayyali, T., Qutranji, L., Kaya, E., Bakir, A. & Yilmaz, Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol. 57, 613–618 (2020).

pubmed: 31897769 doi: 10.1007/s00592-019-01467-7

Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. lancet Gastroenterol. Hepatol. 8, 714–725 (2023).

pubmed: 36958367 doi: 10.1016/S2468-1253(23)00017-1

Jiang, K. et al. Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls. BMC Gastroenterol. 22, 37 https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02108-0 (2022).

pubmed: 35090390 pmcid: 8800333 doi: 10.1186/s12876-022-02108-0

Ibrahim S. H., Malhi H. A molecular signature of mouse NASH: a step closer to a human predictive biomarker? Cell Mol. Gastroenterol. Hepatol. 5, 65–66 (2018).

van Koppen, A. et al. Uncovering a predictive molecular signature for the onset of NASH-related fibrosis in a translational NASH Mouse Model. Cell Mol. Gastroenterol. Hepatol. 5, 83–98.e10 (2018).

pubmed: 29276754 doi: 10.1016/j.jcmgh.2017.10.001

Morrison, M. C., Kleemann, R., van Koppen, A., Hanemaaijer, R. & Verschuren, L. Key inflammatory processes in human NASH Are Reflected in Ldlr(-/-).Leiden Mice: a Translational Gene Profiling Study. Front. Physiol. 9, 132 (2018).

pubmed: 29527177 pmcid: 5829089 doi: 10.3389/fphys.2018.00132

Martínez-Arranz, I. et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology 76, 1121–1134 (2022).

pubmed: 35220605 doi: 10.1002/hep.32427

Castañé, H. et al. Coupling machine learning and lipidomics as a tool to investigate metabolic dysfunction-associated fatty liver disease. a general overview. Biomolecules 11, 473 (2021).

pubmed: 33810079 pmcid: 8004861 doi: 10.3390/biom11030473

Hwa, V., Oh, Y. & Rosenfeld, R. G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20, 761–787 (1999 Dec).

pubmed: 10605625

Jin, L., Shen, F., Weinfeld, M. & Sergi, C. Insulin growth factor binding protein 7 (IGFBP7)-related cancer and IGFBP3 and IGFBP7 Crosstalk. Front. Oncol. 10, 727 (2020).

pubmed: 32500027 pmcid: 7242731 doi: 10.3389/fonc.2020.00727

Liu, L. X. et al. Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro. World J. Gastroenterol. 15, 3246–3253 (2009).

pubmed: 19598300 pmcid: 2710780 doi: 10.3748/wjg.15.3246

Yao, K. et al. Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. Hepatol. Commun. 6, 1598–1610 (2022).

pubmed: 35312185 pmcid: 9234638 doi: 10.1002/hep4.1940

Yan, H. et al. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease. Clin. Exp. Pharmacol. Physiol. 46, 1101–1110 (2019).

pubmed: 31397492 doi: 10.1111/1440-1681.13159

Gonçalves, C. M. et al. Molecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily. Mol. Immunol. 46, 2585–2596 (2009).

pubmed: 19535143 doi: 10.1016/j.molimm.2009.05.006

Ge, Y. et al. The serum soluble scavenger with 5 domains levels: a novel biomarker for individuals with heart failure. Front. Physiol. 14, 1140856 (2023).

pubmed: 37123263 pmcid: 10133869 doi: 10.3389/fphys.2023.1140856

Lontos, K. et al. The role of semaphorin 4D in bone remodeling and cancer metastasis. Front. Endocrinol. 9, 322 (2018).

doi: 10.3389/fendo.2018.00322

Laber, A., Gadermaier, E., Wallwitz, J., Berg, G. & Himmler, G. A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma. Anal. Biochem. 574, 15–22 (2019).

pubmed: 30879960 doi: 10.1016/j.ab.2019.03.004

Šamadan, L. et al. Do semaphorins play a role in development of fibrosis in patients with nonalcoholic fatty liver disease? Biomedicines 10, 3014 (2022).

pubmed: 36551769 pmcid: 9775767 doi: 10.3390/biomedicines10123014

BLIGH, E. G. & DYER, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911–917 (1959).

pubmed: 13671378 doi: 10.1139/y59-099

Decaris, M. L. et al. Proteomic analysis of altered extracellular matrix turnover in bleomycin-induced pulmonary fibrosis. Mol. Cell Proteom. 13, 1741–1752 (2014).

doi: 10.1074/mcp.M113.037267

Price, J. C. et al. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. Anal. Biochem 420, 73–83 (2012).

pubmed: 21964502 doi: 10.1016/j.ab.2011.09.007

Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).

pubmed: 20979621 pmcid: 3218662 doi: 10.1186/gb-2010-11-10-r106

Wimmer, I. et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Sci. Rep. 8, 6351 (2018).

pubmed: 29679021 pmcid: 5910432 doi: 10.1038/s41598-018-24781-6

Troelstra, M. A. et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: the Amsterdam NAFLD-NASH cohort. J. Magn. Reson. Imaging 54, 1937–1949 (2021).

pubmed: 33991378 pmcid: 9290703 doi: 10.1002/jmri.27703

Vreeken, D. et al. Factors associated with cognitive improvement after bariatric surgery among patients with severe obesity in the Netherlands. JAMA Netw. open 6, e2315936 (2023).

pubmed: 37252738 pmcid: 10230316 doi: 10.1001/jamanetworkopen.2023.15936

Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).

pubmed: 15915461 doi: 10.1002/hep.20701

Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P. & Neuschwander-Tetri, B. A. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53, 810–820 (2011).

pubmed: 21319198 doi: 10.1002/hep.24127

Ke, G. et al. LightGBM: a highly efficient gradient boosting decision tree. Adv. Neural Inf. Process Syst. 2017-Decem(Nips), 3147–3155 (2017).

Ayyanar M. et al. Predicting the cardiac diseases using SelectKBest method equipped light gradient boosting machine. 2022 6th International Conference on Trends in Electronics and Informatics (ICOEI). IEEE 3, 117–122 (2022).